アブストラクト
Japanese
| Title | アトピー性皮膚炎の新しい治療 |
|---|---|
| Subtitle | 総説 |
| Authors | 加藤則人 |
| Authors (kana) | |
| Organization | 京都府立医科大学大学院医学研究科皮膚科学 |
| Journal | 日本小児アレルギー学会誌 |
| Volume | 35 |
| Number | 3 |
| Page | 233-238 |
| Year/Month | 2021 / |
| Article | 報告 |
| Publisher | 日本小児アレルギー学会 |
| Abstract | 抄録: 近年, アトピー性皮膚炎の病態に関する研究が飛躍的な進歩を遂げ, その研究成果をもとに, 新しい作用機序を持つアトピー性皮膚炎の治療法の開発が盛んである. Interleukin-4, -13のシグナルを阻害するデュピルマブや, ヤヌスキナーゼ阻害外用薬のデルゴシチニブなど, すでに国内の臨床現場で成人アトピー性皮膚炎を対象に承認されている薬剤も含め, アレルギー炎症に重要な役割を有する2型サイトカインに対するモノクローナル抗体, ヤヌスキナーゼ阻害薬, フォスフォジエステラーゼ4阻害薬の中から, おもなものについて紹介した. これらの一部については, 小児を対象にした臨床研究も進んでいるようである. アトピー性皮膚炎を対象にした新たな治療薬の開発は盛んで, 今後もさらに多くの薬剤が承認されると期待される. アトピー性皮膚炎では, 長期の寛解維持が重要であり, 効果とともに安全性に関する長期データを注視して行く必要がある. |
| Practice | 臨床医学：内科系 |
| Keywords | 2型サイトカイン, デュピルマブ, ヤヌスキナーゼ阻害薬, フォスフォジエステラーゼ4阻害薬, dupilumab, Janus kinase inhibitor, phosphodiesterase 4 inhibitor, type 2 cytokine |
English
| Title | Future perspective of the treatment for pediatric atopic dermatitis |
|---|---|
| Subtitle | |
| Authors | Norito Katoh |
| Authors (kana) | |
| Organization | Department of Dermatology, Kyoto Prefectural University Graduate School of Medical Science |
| Journal | The Japanese Journal of Pediatric Allergy and Clinical Immunology |
| Volume | 35 |
| Number | 3 |
| Page | 233-238 |
| Year/Month | 2021 / |
| Article | Report |
| Publisher | Japanese Society of Pediatric Allergy and Clinical Immunology |
| Abstract | Summary: Recent progress in researches about the pathogenesis of atopic dermatitis (AD) and the expansion of biotechnology and pharmacology have contributed to the development of novel pharmacological agents for AD. Many pharmaceutical agents, including biologics targeting type 2 cytokines, which play pathogenetic roles in AD, e.g. interleukin (IL)-4, IL-13, and IL-31, Janus kinase inhibitors, and phosphodiesterase 4 inhibitors have been developed. These agents are expected to be effective in AD patients with skin signs and/or symptoms that are refractory to conventional treatments including topical corticosteroids and calcineurin inhibitors. Some of them have been studied regarding the efficacy and safety in pediatric patients with AD. In the management of AD, maintenance of long-term remission in addition to achieving remission is important. The safety profile of novel pharmaceutical agents not only in clinical studies but also in the real world should be observed carefully for a long time. |
| Practice | Clinical internal medicine |
| Keywords | dupilumab, Janus kinase inhibitor, phosphodiesterase 4 inhibitor, type 2 cytokine |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) 加藤則人, 他. アトピー性皮膚炎診療ガイドライン2018. 日本皮膚科学会雑誌 2018; 128: 2431-2502.
- 2) Katoh N. Emerging treatments for atopic dermatitis. J Dermatol 2021; 48: 152-157.
- 3) ClinicalTrials.gov. https://clinicaltrials.gov/ (Accessed 2021-2-25)
- 4) Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-2348.
- 5) Blauvelt A, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287-2303.
残りの22件を表示する
- 6) Simpson EL, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156: 44-56.
- 7) Paller AS, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 2020; 83: 1282-1293.
- 8) Achten R, et al. Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract 2020; S2213-2198(20)31091-6 doi:10.1016/j.jaip.2020.09.042.
- 9) Popovic B, et al. Structural characterization reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2. J Mol Biol 2017; 429: 208-219.
- 10) Wollenberg A, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2020; doi:10.1111/bjd.19574.
- 11) Ultsch M, et al. Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab. J Mol Biol 2013; 425: 1330-1339.
- 12) Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis a phase 2 b randomized clinical trial. JAMA Dermatol 2020; 156: 411-420.
- 13) Yang TLB, Kim BS. Pruritus in allergy and immunology. J Allergy Clin Immunol 2019; 144: 353-360.
- 14) Kabashima K, et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med 2020; 383: 141-150.
- 15) O'Shea JJ, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015; 66: 311-328.
- 16) Solimani F, et al. Emerging topical and systemic JAK Inhibitors in dermatology. Front Immunol 2019; 10: 2847 doi:10.3389/fimmu.2019.02847.
- 17) Nakagawa H, et al. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol 2018; 178: 424-432.
- 18) Nakagawa H, et al. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol 2019; 144: 1575-1583.
- 19) Simpson E, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242-255.
- 20) Parmentier JM, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatology 2018; 2: 23.
- 21) Guttman-Yassky E, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020; 145: 877-884.
- 22) Nezamololama N, et al. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context 2020; 9: 2020-8-5 doi:10.7573/dic.2020-8-5.
- 23) Melinda J, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol 2019; 155: 1371-1379.
- 24) Gadina M, et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology(Oxford) 2019; 58: i4-i16.
- 25) Samrao A, et al. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 2012; 148: 890-897.
- 26) Paller AS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016; 75: 494-503.
- 27) Saeki H, et al. Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA-15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis. J Dermatol 2020; 47: 17-24.
